LAVA Therapeutics N.V. logo

LAVA Therapeutics (LVTX) stock

LVTX · LAVA Therapeutics N.V. · NASDAQ

Website

What is the latest news on LVTX stock?

SECago
Amendment: SEC Form 25-NSE/A filed by LAVA Therapeutics N.V.

25-NSE/A - LAVA Therapeutics NV (0001840748) (Subject)

All LVTX news

When does LAVA Therapeutics report earnings?

The latest LAVA Therapeutics earnings release came out on Jun 1, 2022: LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma...

LVTX earnings history

Latest news

25 items

LAVA Therapeutics N.V. (LVTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for LVTX in the last 30 days. The most recent was published Nov 21, 2025.

Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX FAQ

7 questions
  • What does LAVA Therapeutics N.V. do?
    Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of...
  • Where does LVTX stock trade?
    LAVA Therapeutics N.V. (LVTX) is listed on NASDAQ.
  • What sector and industry is LVTX in?
    LAVA Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did LAVA Therapeutics N.V. go public?
    LAVA Therapeutics N.V. (LVTX) completed its IPO in 2021.
  • What are analysts saying about LVTX?
    Across the last 5 analyst actions on LAVA Therapeutics N.V., there were 0 upgrades and 2 downgrades. The most recent action was from Leerink Partners: Market Perform with a $2.00 price target on 2024-12-12.
  • What companies are similar to LVTX?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare LVTX side-by-side with any of them on Quantisnow.
  • How can I track LVTX on Quantisnow?
    Quantisnow aggregates LAVA Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LVTX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change